Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Narconon Fresh Start Launches Efforts to Educate Parents about the Dangers in the Rise of Schedule 2 Stimulant Abuse
  • USA - English


News provided by

Narconon Fresh Start

Feb 26, 2014, 20:20 ET

Share this article

Share toX

Share this article

Share toX

Los Angeles, CA (PRWEB) February 26, 2014 -- Narconon Fresh Start announced today that their company is in the process of creating a new division of their organization that is dedicated to helping inform the general public on the hazards of giving children schedule 2 stimulants to treat ADD, ADHD and other behavioral problems. In the near future, this section of their organization will be launching an informational website where they offer advice and answers to questions by skilled drug counselors through live chat, current news articles on schedule 2 stimulant use, abuse and addiction, a blog where site users can join in the discussion and summit comments. Also included, will be an educational video gallery with documentaries and informative videos about psychiatry, psychiatric medications and psychiatric disorders. As a leader in the fight against drug addiction and alcoholism, Narconon Fresh Start is gaining recognition from renowned psychiatrists such as Dr. Peter Breggin and his colleagues for their efforts to educate parents and caregivers about the dangers of medicating their children with schedule 2 drugs.

Included in their upcoming website on the dangers of children and young adults being prescribed schedule 2 medications are facts and reports from leaders in the field of psychiatry, psychology and addiction rehabilitation. The material will include information on how the use of schedule 2 medications is leading to devastating side effects; side effects that include addiction, anxiety, insomnia and heart palpitations for the children who are on the receiving end of these substances (http://ritalinsideeffects.net). Contained within their upcoming site will be current facts and reports from the CDC (http://www.cdc.gov/nchs/slaits/nsch.htm) and WND.com (http://www.wnd.com/2013/04/radical-increase-in-kids-prescribed-ritalin/) which state that there are as many as 6.4 million children ages 4-17 diagnosed with ADD or ADHD, with approximately two-thirds of these children being prescribed Ritalin or Adderall.

Their educational website will include research by Nadine Lambert, PhD, director of the school psychology program at the University of California at Berkeley who has identified a relationship between both ADHD and the use of stimulants in childhood and dependence on tobacco and other stimulants as adults (http://www.berkeley.edu/news/berkeleyan/1999/0512/ritalin.html). Her explanation for these findings are that either today’s youth are self-medicating to feel better; or, that they become more sensitive to the effects of stimulants e.g. Ritalin and therefore are more susceptible to other stimulants (cocaine, meth, etc.) as they grow up. Narconon Fresh Start’s efforts to educate the public and change the policy on what is medically acceptable are seen as a step in the right direction by leaders in the field of psychiatry and psychology.

Narconon Fresh Start is a strong supporter of psychiatrist Dr. Peter Breggin, author of numerous books including Toxic Psychiatry. Dr. Breggin is a forthright advocate on stopping what he believes is the overmedicating of America’s children. His recent articles and lectures are on the cutting edge in his field as he continues to shine a light on what is going on behind the scenes of psychiatry. While never holding back on the truth about psychiatry, Dr. Breggin notes in his 1998 video, included on the new site to be launched, "Talking Back to Ritalin", (http://www.youtube.com/watch?v=n0SHflAfJwo) that today’s psychiatry is driven by politics, not science. He shares that parents, care givers, teachers, and pediatricians are given incorrect information intended to help the children in their care; however this information has been so filtered through the drug companies as well as the psychiatric foundation that the facts they are receiving are not an accurate representation of the dangers these medications can have on their children.

A parent of a recent graduate from Narconon Fresh Start’s drug rehab program (http://www.drugrehab.com) shares “If I had fully understood the long-term effects of Ritalin and the increased risk of my son developing a substance abuse problem I would have steered clear of putting him on such a toxic medication for his ADHD.” Today, many parents, families, teachers and other providers are feeling the same way and are now researching the consequences of putting children on such highly addictive schedule 2 medications. Soon, they will be able to utilize Narconon Fresh Start’s new website in their efforts to become educated on the many dangers of schedule 2 medications such as Ritalin and Adderall and make an informed decision about what is right for the children in their care.

Jay Farrell, Narconon Fresh Start, http://www.drugrehab.com, +1 855-734-2223, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.